---
title: "Basecamp Research Raises $140M Series C for AI-Designed Cell Therapies"
description: "Basecamp Research closed a $140 million Series C led by S32 to move its biological foundation models toward preclinical cell-therapy programs."
date: 2026-09-25T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-basecamp-research-140m-series-c-ai-therapeutics
---

# Basecamp Research Raises $140M Series C for AI-Designed Cell Therapies

> Basecamp Research closed a $140 million Series C led by S32 to move its biological foundation models toward preclinical cell-therapy programs.

**Basecamp Research closed a $140 million oversubscribed Series C** on September 23, 2026. **S32** led the round. Nvidia, the NATO Innovation Fund, Anthropic's Anthology Fund, Catalio, Redalpine, Singular, True Ventures and other investors participated.

## Deal terms

| Field | Detail |
| --- | --- |
| Company | [Basecamp Research](/startup/basecamp-research) |
| Financing | **$140M Series C** |
| Lead | S32 |
| Selected participants | Nvidia; NATO Innovation Fund; Anthology Fund; Catalio; Redalpine; Singular; True Ventures |
| Valuation | Not disclosed |
| Status | Company announced |

## Why this financing matters

Basecamp is trying to differentiate its biological models with proprietary data gathered through global biodiversity partnerships. The Series C is intended to move that data-and-model platform into AI-designed therapeutic programs, including in-vivo cell therapies.

The investor group combines AI infrastructure, defence-linked innovation capital and specialist life-sciences funds. That mix reflects the breadth of the platform story, but the next proof points will come from biology rather than model benchmarks.

## The clinical reality

The programs remain preclinical. Basecamp did not disclose human-trial timelines, revenue, partnership economics or a valuation. Any claims about model quality or therapeutic performance should remain attributed to the company until validated through published studies and clinical results.

## Bottom line

The confirmed event is a **$140 million Series C**. It gives Basecamp the capital to translate a biological foundation-model thesis into drug programs, where timelines, safety and efficacy will determine whether the data advantage is real.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.